RG 7203

Drug Profile

RG 7203

Alternative Names: RG7203

Latest Information Update: 29 Jul 2015

Price : $50

At a glance

  • Originator Roche
  • Class Antipsychotics; Small molecules
  • Mechanism of Action Phosphodiesterase 10A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Schizophrenia

Most Recent Events

  • 29 Jul 2015 Discontinued - Phase-I for Schizophrenia in Switzerland (unspecified route)
  • 16 Oct 2014 Roche completes a phase I trial in Schizophrenia in Switzerland
  • 15 Oct 2014 Roche initiates enrolment a phase I trial for Schizophrenia in Switzerland before October 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top